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Background: The sentinel lymph node procedure has been proposed to improve nodal
staging in colon cancer patients. The aim of this study was to assess the added value of
near-infrared (NIR) fluorescence imaging to conventional blue dye staining for ex vivo
sentinel lymph node mapping.
Materials and methods: We included 22 consecutive patients undergoing surgery for colon
cancer. After tumor resection, we submucosally injected a premixed cocktail of the near-
infrared lymphatic tracer HSA800 and blue dye around the tumor for detection of
sentinel lymph nodes. We used the Mini-FLARE imaging system for fluorescence imaging.
Results: In 95% of patients, we identified at least one sentinel lymph node. Overall, a total of
77 sentinel lymph nodes were identified, 77 of which were fluorescent (100%) and 70 of
which were blue (91%). Sentinel lymph nodes that were located deeper in the mesenteric
fat could easily be located by NIR fluorescence. In four of five patients with lymph node
metastases, tumor cells were present in at least one of the sentinel lymph nodes.
Conclusions: This study shows the successful use and added value of the NIR fluorescence
tracer HSA800 to conventional blue dye for the ex vivo sentinel lymph node procedure in
colon cancer.
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recurrence [1,2]. This is most likely caused by understaging
during the initial procedure.
Correct nodal staging depends onmultiple factors, including
number of examined nodes [3]. Moreover, occult tumor cells
and micrometastases are easily missed by conventional his-
topathologic examination. Various retrospective studies have
shown poor prognosis for patients with micrometastases
compared with patients without metastases [4,5]. Multiple
clinical trails are currently ongoing in which patients with
micrometastatic disease are treated with adjuvant chemo-
therapy, which is currently not considered for this indication
[6]. However, detection of micrometastases often requires
ultrastaging techniques for each lymph node using serial
sectioning and additional immunohistochemistry or reverse
transcriptaseepolymerase chain reaction [7,8]. However, this is
currentlybeyondstandardhistopathologic analysisand is time-
consuming, and expensive. To overcome this disadvantage, the
sentinel lymph node (SLN) procedure for colon cancer patients
has been evaluated extensively [9].
Sentinel lymph node are the first lymph nodes that receive
lymphatic drainage from the tumor, and identification of the
SLN and analysis for tumor involvement could predict the
tumor status of the remaining lymph nodes. Therefore,
the SLN procedure in colon cancer can be a useful tool to select
the nodes for ultrastaging [4]. In colon cancer patients, both
blue dyes and radiotracers have been used as SLN tracers
in an in vivo and ex vivo setting [9]. However, both have
disadvantages. The use of gamma rayeemitting radiotracers
requires involvement of a nuclear medicine physician, and
localization requires a handheld gammaprobe, which doesnot
permit real-time visualization. Also, preoperative access to the
injection site is often required, which in colon cancer patients
requires endoscopic injection. Blue dyes cannot be easily seen
through fatty tissue and can easily diffuse through the true
SLN to second- to third-tier nodes because of their small size.
Recently, optical imaging using near-infrared (NIR) fluo-
rescence has been introduced for real-time visualization
of structures during surgery. Advantages of NIR fluorescent
(700e900 nm) light include high tissue penetration (several
millimeters) and low autofluorescence of tissue in this
wavelength region, thereby providing high contrast. To date,
indocyanine green is the only clinically available NIR fluo-
rescent tracer and has been used with success for the SNL
procedure in several types of cancer including gastrointestinal
cancer [10e18]. However, because of relative low fluorescence
brightness (quantum yield) and poor SLN retention, indoc-
yanine green is not an ideal SLN tracer [19]. To improve
retention of the NIR tracer in the SLN, conjugation of an NIR
fluorescent dye, such as IRDdye 800CW, to a larger molecule,
such as human serum albumin (HSA; complex: HSA800) is
recommended [19]. However, because HSA800 is not yet clin-
ically approved, it can only be used for ex vivo SLN mapping.
Previously, our group used HSA800 successfully ex vivo in
a feasibility study with patients with colon cancer, and we
were able to identify SLNs in all patients [20]. However, in our
earlier study we used no blue dye staining because blue dyes
might interfere with NIR fluorescence imaging by absorbing
the fluorescent light and thereby decreasing the identification
rate. At present, blue dye staining is frequently used for theex vivo SLN procedure, and blue dye staining also provides
visual information, which could make it easier to identify
and resect SLNs. The aims of this study were to assess the
feasibility of the combined use of NIR fluorescence using
HSA800 and blue dye staining, and to assess the added value
of NIR fluorescence to blue dye staining for SLN mapping
in colon cancer patients.2. Materials and methods
2.1. Preparation of lymphatic tracers
The preparation of HSA800 (IRDye 800CW conjugated to HSA)
has been described in detail previously [19]. Briefly, after
conjugation of CW800-NHS to albumin, we purified HSA800
using a 7K Zeba Spin Desalting Column (Thermo Scientific,
Rockford, IL). The ratio of fluorophore (IRDye 800CW; Li-Cor,
Lincoln, NE) to albumin (HSA) was 1.5:1, estimated using the
extinction coefficients of HSA (ε280 nm ¼ 32,900 mol/L1cm1)
and CW800 (ε778 nm ¼ 240,000 mol/L1cm1) in phosphate-
buffered saline, with a stock concentration of approximately
600 mmol/L. Peak absorbance and emission of HSA800 were
778 and 795 nm, respectively. To obtain a solution of 50 mmol/L
HSA800, we diluted 50 nmol HSA800 in 1 mL patent blue (Bleu
Patente´ V; Guerbet, Brussels, Belgium) before injection.
2.2. Intraoperative NIR imaging system (Mini-FLARE)
We performed clinical SLN mapping using the Mini-FLARE
imaging system, which has been described in detail else-
where [21,22]. Briefly, the system consists of two wavelength-
isolated light sources: a white light source, generating 26,600
lx of 400- to 650-nm light and an NIR light source, generating
7.7mW/cm2 of 760-nm light. Color video and NIR fluorescence
images are simultaneously acquired and displayed in real
time using custom optics and software that separate the color
video and NIR fluorescence images. A pseudo-colored (lime
green) merged image of the color video and NIR fluorescence
images is also displayed. The imaging head is attached to
a flexible gooseneck arm, which permits positioning of the
imaging head virtually anywhere over the surgical field and
at extreme angles.
2.3. Clinical trial
We enrolled 22 consecutive patients undergoing surgery with
curative intent for colon cancer. Patients with known meta-
static disease were excluded. The Leiden University Medical
Center Medical Ethics Committee approved this study, which
we performed in accordance with the Declaration of Helsinki.
All known patients underwent a standard oncological resec-
tion including a segmental colonic resection and lymphade-
nectomy. Tumors were endoscopically marked before surgery
when indicated. Directly after resection, the resection specimen
was freshly delivered to the Department of Pathology, where
the specimen was opened antimesenterically by the patholo-
gist. Subsequently, 1 mL of 50 mmol/L HSA800 diluted in patent
blue was injected submucosally circumferentially with a 5-mm
margin around the tumor. The injection site was massaged for
Table 1 e Patient and tumor characteristics.
Characteristic N %
Gender
Male 12 55
Female 10 45
Age, median (range) 69 (41e88)
Body mass index, median (range) 25 (20e40)
Tumor size, cm, median (range) 3.7 (0.9e9.0)
Tumor location
Cecum 3 13
Ascending colon 9 41
Transverse colon 1 5
Sigmoid colon 9 41
Tumor differentiation
Well 1 5
Moderately 17 77
Poorly 4 18
Tumor invasion
T1 2 9
T2 7 32
T3 10 46
T4 3 13
Table 2 e Results of sentinel lymph node procedure.
Characteristic N %
Detection rate 21 95
SLNs detected per patient
0 1 5
1 3 13
2 2 9
3 6 28
4 3 13
5 4 18
6 1 5
7 2 9
>7 0 0
Method of detection
Fluorescence and blue staining 70 91
Fluorescence only 7 9
Number of total dissected nodes, median (range) 21 (11e38)
Histology
Negative 17 77
Positive 5 23
False negatives 1 20
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the SLN in both an in vivo and ex vivo setting [20]. After 5 min,
the specimen was inspected using the Mini-FLARE camera
system and by visual inspection. We allocated all fluorescent
hotspots as SLN and noted whether these nodes were stained
blue. The SLNs were separately fixated in 2% buffered formalin
for 24 h. After fixation,we harvested all remaining lymphnodes
from the specimen and paraffin-embedded all lymph nodes
(sentinel and nonsentinel); 4-mm sections were stained with
hematoxylin-eosin and subsequently analyzedmicroscopically
for the presence of tumor cells.3. Results
We enrolled 22 consecutive patients undergoing surgery for
colon cancer. Table 1 lists patient and tumor characteristics.
Of these 22 patients, the median age was 69 y (range, 41e88 y);
median body mass index was 25 kg/m2 (range, 20e40 kg/m2).
A total of 12 patients were male. Tumor invasion ranged from
stage T1 to T4. The median tumor size was 3.7 cm (range,
0.9e9 cm). Four patients had a poorly differentiated tumor,
17 patients had a moderately differentiated tumor, and one
had a well-differentiated tumor. Twelve patients received
preoperative endoscopic tattooing of the tumor.
After administration of the lymphatic tracer cocktail, at
least one SLNwas identified in 21 of 22 patients (95%) (Table 2).
Sentinel lymph nodes that were located deeper in the
mesenteric fat could easily be located by NIR fluorescence
but not with the blue dye. After the pathologist subsequent
incised the mesentery, in most cases, blue staining of the
lymph node was also detected, which provided the patholo-
gist with direct visual support (Fig.). On average, 3.5  1.9
SLNs/patient were identified. Overall, a total of 77 SLNs were
identified, of which 77 (100%) were fluorescent and 70 (91%)
were blue (Pearson’s correlation coefficient, 0.94). In five
patients, fluorescent SLNs were identified (average 1.4  0.5
nodes/patient) that were not stained blue. A total (sentineland nonsentinel) of 20.5  8.1 nodes were harvested on
average from each specimen. Standard histologic analysis
showed that five of 22 patients had lymph nodemetastases. In
all but one of these five patients, tumor cells were present in
at least one of the SLNs. The false-negative (neither fluores-
cent nor blue) lymph node was almost completely filled with
tumor cells and was easily detected by the pathologist.4. Discussion
Nodal status in colon cancer is the most important prognostic
factor, which makes it crucial in deciding whether a patient
should be considered for adjuvant treatment. Therefore, the
main purpose of the SLN procedure in colon cancer patients
is the selection of lymph nodes to be assessed by ultrastaging
techniques. The current study shows the successful use of NIR
fluorescence imaging in combination with blue dye during
ex vivo SLN mapping in colon cancer. The NIR fluorescent
tracer HSA800 permitted detection of the SLN located deeper
into themesenteric fat. The detection rate of 95% in this study
is in concordance with previously reported detection rates
in SLN mapping using radiotracers, blue dyes, or a combina-
tion of both [9].
This is the first study in which an NIR fluorescent tracer is
used in combination with conventional blue dye staining,
which is most commonly used as lymphatic tracer, in the
ex vivo SLN procedure. Because NIR fluorescence imaging is
capable of penetrating millimeters into tissue, it allowed
identification of small amounts of the lymphatic tracer deeper
into the mesenteric fatty tissue. Moreover, owing to the high
spatial resolution of NIR fluorescence, we observed no inter-
ference between the fluorescent signal of the injection site and
SLNs.WepremixedHSA800with patent blue, andwe therefore
anticipated staining the same nodes NIR fluorescent and blue.
Indeed, there was a high correlation between identification
using fluorescence and identification using blue dye staining.
However, several fluorescent nodes (9%) did not stain blue.
Fig. e Sentinel lymph node mapping using NIR fluorescence and blue dye in colon cancer. (Upper) Peritumoral submucosal
injection (arrows) of 1.0 mL of 50 mmol/L HSA800 and patent blue. (Middle) Identification of the SLN (arrowheads) by NIR
fluorescence located in the mesenteric fat near the injection site (arrows). The NIR fluorescence signal is scattered
(i.e., blurred) by the mesenteric fat covering the node. (Lower) After incision of the mesentery by the pathologist, a clear blue
and fluorescent SLN (arrowhead) can be identified. Camera exposure times were 25ms (upper panel), 100ms (middle panel),
and 67 ms (lower panel). Scale bars [ 1 cm. (Color version of figure is available online.)
j o u r n a l o f s u r g i c a l r e s e a r c h 1 8 3 ( 2 0 1 3 ) 2 5 3e2 5 7256Possible explanations could be the high sensitivity of NIR
fluorescence imaging, which allows detection of low concen-
trations of the tracer, and dilution of the blue dye to concen-
trations not visible with the human eye [23e25]. Because
there appears to be little interference of blue dye with NIR
fluorescence, in most cases blue staining could be used as
complementary direct visual support to assist the pathologist
in resecting the SLNs.
Preoperative tattooing of the tumor, which is mostly used
for tumor localization during laparoscopic surgery, can result
in staining of lymph nodes and has been suggested for SLN
mapping [26e29]. In the current study, multiple patients re-
ceived preoperative endoscopic tattooing of the tumor, which
resulted in multiple blue colored nodes before the SLN proce-
dure. Because it appeared to be difficult to differentiate between
staining by endoscopic tattooing and patent blue staining, the
blue dye staining could be less reliable for detecting the first
echelon nodes in the current study. Therefore, in patients who
received preoperative endoscopic tattooing, the use of NIR
fluorescence imaging could overcome these problems.
One false-negative case occurred out of five patients with
nodal metastases, which is in concordance with other, earlier
studies [9,30]. In the current study, we identified the SLNs
approximately 15 min after injection of HSA800, which adds
extra time to the standard workup. In addition, identification
of the SLN can be difficult, because not all lymph nodes can be
exposed. Identification of SLNs after fixation would allow
the pathologist to identify the SLN during routine practice.
When SLN detection is performed several hours after injection,
optimal retention of the lymphatic tracer in the SLN tracer is
essential. However, HSA800 still migrates to higher-echelonlymph nodes, albeit slower than small molecules such as
patent blue [19]. When improved retention in the SLN is
wanted, nanocolloidal albumin combined with fluorescence
can be used, which provides optimal retention in the SLN
because of its favorable large hydrodynamic diameter and
charge [19,31e33]. Moreover, rather than being only potentially
useful for pathologic staging, in vivo SLN mapping has been
suggested for patient-tailored extent of surgery [11,34,35].
Clinical approval of HSA800 would also allow in vivo NIR fluo-
rescence SLN mapping using this tracer.
This study demonstrated the successful use of a combina-
tion of an NIR fluorescence tracer and a conventional blue dye
for the ex vivo SLN detection in colon cancer, which can be
used as a tool to select the nodes for ultrastaging techniques
to identify micrometastases and improve nodal staging. Near-
infrared fluorescence was of added value compared with blue
dye staining, because NIR fluorescence allowed detection of
additional SLNs and easy detection of SLNs located deeper
into the mesenteric fat. Moreover, NIR fluorescence cannot be
confusedwith blue nodal staining resulting from preoperative
tattooing of the tumor.
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